Follow the evidence, wherever it leads
Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database
To evaluate the difference in mortality,
Patients treated with ivermectin
Patients treated with remdesivir
44 healthcare organizations and 68 million patients from US,
January 1, 2020 and July 11, 2021
Methods & Materials
Retrospectively identified diagnosed adults
Recorded use of ivermectin, but not remdesivir
Recorded use of remdesivir, but not ivermectin
Controlled for, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.
Primary outcome assessed, mortality
Sith significance assessed at p less than 0.05.
41,608 patients who had COVID-19
Treated with ivermectin n = 1,072
Treated with remdesivir n = 40,536
Ivermectin was associated with reduced mortality vs remdesivir
p less than 0.0001.
Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir.
In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching (Brazil)
Ivermectin has demonstrated different mechanisms of action, coronavirus infection and COVID-19-related comorbidities.
Prophylaxis combined with the known safety profile of ivermectin
Study to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.
Prospective, July 2020 and December 2020
Inviting the entire population of Itajaí to a medical visit to enroll in the program,
ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day.
Study analysis consisted of comparing ivermectin users with non-users using cohorts
223,128 citizens of Itajaí considered
159,561 included in the analysis
113,845 (71.3%) regular ivermectin users
45,716 (23.3%) non-users
4,311 ivermectin users were infected, (3.7% infection rate)
3,034 non-users (6.6% infection rate)
A 44% reduction in COVID-19 infection rate
Risk ratio (RR), 0.56
The regular use of ivermectin led to a 68% reduction in COVID-19 mortality
25 (0.8%) deaths in the ivermectin group
79 (2.6%) among ivermectin non-users
p less than 0.0001
When adjusted for residual variables, reduction in mortality rate was 70%
There was a 56% reduction in hospitalization rate
44 in the ivermectin group
99 in non ivermectin users
After adjustment for residual variables, reduction in hospitalization rate was 67%
p less than 0.0001
In this large study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.